J7J Stock Overview
Focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Monogram Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.71 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$1.33 |
| Beta | 0 |
| 1 Month Change | -3.39% |
| 3 Month Change | -11.40% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| J7J | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -18.6% | -2.4% | -3.1% |
| 1Y | n/a | -2.2% | -0.5% |
Return vs Industry: Insufficient data to determine how J7J performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how J7J performed against the German Market.
Price Volatility
| J7J volatility | |
|---|---|
| J7J Average Weekly Movement | 32.3% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: J7J's share price has been volatile over the past 3 months.
Volatility Over Time: J7J's weekly volatility has increased from 25% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 28 | Ben Sexson | www.monogramorthopedics.com |
Monogram Technologies Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens.
Monogram Technologies Inc. Fundamentals Summary
| J7J fundamental statistics | |
|---|---|
| Market cap | €60.95m |
| Earnings (TTM) | -€12.51m |
| Revenue (TTM) | €341.02k |
178.7x
P/S Ratio-4.9x
P/E RatioIs J7J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J7J income statement (TTM) | |
|---|---|
| Revenue | US$365.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$365.00k |
| Other Expenses | US$13.76m |
| Earnings | -US$13.39m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,669.65% |
| Debt/Equity Ratio | 0% |
How did J7J perform over the long term?
See historical performance and comparison